Exploring genetic factors in malignant pleural mesothelioma
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS
This study is trying to see if certain genetic factors make people more likely to develop malignant pleural mesothelioma after being exposed to asbestos.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 2 sites (Pavia, Pavia and 1 other locations) |
| Trial ID | NCT06886672 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the genetic susceptibility of individuals to malignant pleural mesothelioma (MPM), particularly focusing on germline variations and their clinical implications. The study aims to understand how asbestos exposure interacts with genetic predispositions to influence the development of MPM. By analyzing patients diagnosed with MPM and former asbestos-exposed healthy subjects, the research seeks to uncover potential genetic markers that could inform future therapeutic strategies. The study is set in the Pavia province, an area with ongoing asbestos exposure and a rising incidence of MPM.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a documented diagnosis of malignant pleural mesothelioma or former asbestos-exposed healthy individuals.
Not a fit: Patients without a history of asbestos exposure or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of genetic factors in MPM, potentially guiding personalized treatment approaches.
How similar studies have performed: While the role of germline changes in MPM is largely unexplored, similar studies in other cancers have shown promising results in identifying genetic predispositions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria Cohort A: * Patient with a documented diagnosis of MPM (any disease stage and independently from chemo line treatment) * Age ≥ 18 years (there is no upper age limit). * Patient who gives their informed consent to participate in the study Exclusion Criteria Cohort A: * No exclusion criteria Inclusion Criteria Cohort B: * Former asbestos exposed healthy subjects * Age ≥ 18 years (there is no upper age limit). * Subject who gives their informed consent to participate in the study Exclusion Criteria Cohort B: * No exclusion criteria
Where this trial is running
Pavia, Pavia and 1 other locations
- Fondazione IRCCS Policlinico San Matteo — Pavia, Pavia, Italy (Recruiting)
- IRCCS Istituti Clinici Maugeri, Medicina del Lavoro — Pavia, Pavia, Italy (Recruiting)
Study contacts
- Study coordinator: Giulia Maria Stella, MD
- Email: g.stella@smatteo.pv.it
- Phone: +390382503369
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.